Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology.
Overview
The IDE submission represents a significant step for Glucotrack, reflecting the company's progress in preclinical development and technical foundation of the technology. The fully implantable CBGM system is designed to provide long-term, real-time, blood-based accuracy without an on-body wearable.
What it does
The system continually measures blood glucose levels with a sensor longevity of 3 years and minimal calibration. It is intended to offer people with diabetes a new option for continuous glucose monitoring, allowing them to work, exercise, sleep, and socialize without the disruption of frequent sensor changes or visible wearables.
Tradeoffs
The submission of the IDE follows several years of focused engineering, preclinical evaluation, and iterative design work supporting the development of the long-term, fully implantable CBGM system. Data generated to date support advancing the technology into U.S. clinical evaluation. However, the company faces risks relating to the receipt of regulatory approvals, enrollment of patients in clinical trials, and future distribution agreements.
Glucotrack's President and Chief Executive Officer, Paul V. Goode, PhD, stated that the submission of the IDE represents meaningful progress in the development of the CBGM technology and underscores the company's commitment to helping people with diabetes live more fully. The company looks forward to generating the clinical data needed to advance toward regulatory approval and demonstrate that continuous glucose monitoring can be both highly accurate and virtually invisible.
In practical terms, the development of a fully implantable CGM system could significantly improve the quality of life for people with diabetes, providing them with a convenient and discreet way to monitor their blood glucose levels. As the company proceeds with its U.S. clinical study, it will be important to closely monitor the results and assess the potential benefits and risks of this innovative technology.